China Pharma Holdings (CPHI) Cash from Financing Activities (2010 - 2026)

China Pharma Holdings (CPHI) has reported Cash from Financing Activities for 16 consecutive years, with $120118.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities rose 636.22% year-over-year to $120118.0; the trailing twelve-month figure through Jun 2026 stood at -$154013.0 (down 4.98% YoY), and the FY2025 full-year result was -$294027.0, down 770.37% from the prior year.
• Cash from Financing Activities advanced to $120118.0 in Q2 2026 per CPHI's latest filing, from -$79325.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $518237.0 in Q1 2023 and bottomed at -$850555.0 in Q2 2022.
• Historically, Cash from Financing Activities has averaged -$110215.4 across 5 years, with a median of -$38367.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities plunged 1885.97% in 2025, then soared 636.22% in 2026.
• Over 5 years, Cash from Financing Activities stood at -$672063.0 in 2022, then soared by 104.52% to $30378.0 in 2023, then tumbled by 278.86% to -$54333.0 in 2024, then plunged by 33.61% to -$72592.0 in 2025, then soared by 265.47% to $120118.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $120118.0, -$79325.0, and -$72592.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.